Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography

Prostate

Volumn 75, Issue 16, 2015, Pages 1934-1940

  Hijazi, S ^a   Meller, B ^a   Leitsmann, C ^a   Strauss, A ^a   Meller, J ^a   Ritter, C O ^a   Lotz, J ^a   Schildhaus, H U ^a   Trojan, L ^a   Sahlmann, C O ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

68Ga PSMA PET CT; biochemical recurrence; pelvic lymph node dissection; prostate cancer; PSMA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PELVIS LYMPH NODE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84944441847     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23091     Document Type: Article

References (21)

1. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 nsecutive patients: Long-term results. J Urol 2004; 172: 910-914.
2. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ,. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 2012; 110: 1709-1713.
3. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA,. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 2013; 119: 3265-3271.
4. Scher HI, Heller G,. Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 2000; 55: 323-327.
5. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H,. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-1876.
6. 11C-Choline positron emission tomography/computerized tomography. J Urol 2015; 193: 111-116.
7. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo LV, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F,. Pelvic/ retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011; 60: 935-943.
8. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W,. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012; 188: 2190-2197.
9. Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST,. Review of salvage therapy for biochemically recurrent prostate cancer: The role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012; 2012: 921674.
10. Bouchelouche K, Choyke PL, Capala J,. Prostate specific membrane antigen a target for imaging and therapy with radionuclides. Discov Med 2010; 9: 55-61.
11. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Habekorn U, Eisenhut M,. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688-697.
12. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U,. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20.
13. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U,. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014; 41: 1280-1292.
14. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Mol Imaging 2015; 42: 197-209.
15. Martin R, Juttler S, Muller M, Wester HJ,. Cationic eluate pretreatment for automated synthesis of [(68)Ga]CPCR4.2. Nucl Med Biol 2014; 41: 84-89.
16. Fleischmann A, Thalmann GN, Markwalder R, Studer UE,. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005; 23: 2358-2365.
17. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett J, King D, Mehes G,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172.
18. Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ,. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144: 243-245.
19. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW,. Impact of time-of-flight on PET tumor detection. J Nucl Med 2009; 50: 1315-1323.
20. Meller B, Meller J, Sahlmann CO, Hijazi S, Trojan L, Thelen P,. V52 Medikamentöse Beeinflussung der Aufnahme von F-18-Flormethylcholin (FMC) und Ga-68-PSMAHEBD sowie der prostataspezifischen Membranantigen (PSMA)-mRNAExpression in In-vitro-Modellen des Prostatakarzinoms (PC). Nuklearmedizin 2014; 531: A2-A109.
21. Oderda M, Joniau S, Spahn M, G,. Ontero P: Debulking surgery in the setting of very high-risk prostate cancer scenarios. BJU Int 2012; 110: E192-E198.